Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Lipaglyn gives Zydus Cadila first mover advantage in lucrative NASH market, says GlobalData

Following the recent news that The Drug Controller General of India (DCGI) has approved Zydus Cadila’s new drug application (NDA) for Lipaglyn (saroglitazar) for treatment of Non-Cirrhotic, Non-Alcoholic Steatohepatitis (NASH) in India; Nag Madhavi, Healthcare Analyst at GlobalData, a leading data and analytics company, offers her view: “Lipaglyn, which is a novel first in class […]
Read more

MD1003 Phase III trial failure for multiple sclerosis treatment not wholly unexpected

Following the news that MedDay Pharmaceutical’s MD1003 for the treatment of non-active progressive forms of multiple sclerosis (MS) failed in a Phase III clinical trial; Philippa Salter, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, offers her view: “Despite MD1003 demonstrating efficacy at reversing disease progression in a small percentage of […]
Read more

Systemic lupus erythematosus and lupus nephritis market to be worth $1.6bn by 2028 driven by launch of six pipeline therapies, says GlobalData

The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market is expected to grow from $935.9M in 2018 to $1.6bn by 2028 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 5.6%, according to GlobalData, a leading data and analytics company. The company’s latest report, Systemic Lupus Erythematosus and Lupus Nephritis: […]
Read more

Global bladder cancer market set to reach $4.0bn by 2028

The bladder cancer market is expected to significantly grow from $733m in 2018 to $4.0bn by 2028 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 18.5%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Bladder cancer: Opportunity Analysis and Forecast to 2028’, states that the main driver of growth will be the approval and launch of pipeline therapies in multiple treatment […]
Read more

As coronavirus spreads, mitigation may be better strategy than quarantine

The statement from the World Health Organization (WHO) that we are in “uncharted territory” on the coronaries outbreak comes as no surprise as Covid-19 infections are spreading beyond China at an alarming pace, with several clusters of outbreaks being reported in Europe, the Middle East and Asia. Governments should start to consider focusing on mitigation […]
Read more

Cipla’s digital initiatives in respiratory space can be an exemplar for other leading Indian pharma companies, says GlobalData

Digital marketing in pharma is gaining increasing importance in recent times and Indian multinational pharmaceutical company Cipla Limited can be termed as a pioneer in this space from the Indian market perspective as it has successfully used a digital strategy to promote disease awareness and grow leadership position in asthma, says GlobalData, a leading data […]
Read more

Clinical worthiness of microbiome-based approaches for melanoma unclear, says GlobalData

Gut bacteria research is seeing a resurgence in drug development, including beyond gastrointestinal disorders, with pharmaceutical companies diving into microbiome-focused cancer therapeutic candidates. Experts, however, are taking a cautious stance when it comes to treating melanoma, according to reporting by Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and […]
Read more

Innovations in CAR-T therapies across APAC will make global market more competitive, says GlobalData

There are currently 445 chimeric antigen receptor (CAR-T cell) therapies under development by companies headquartered across the Asia-Pacific (APAC) region. With research in progress and increased understanding of cancer biology, the new therapies are expected to make the global market more competitive and cost effective, says GlobalData, a leading data and analytics company. GlobalData’s research […]
Read more

Rare Disease Day 2020: Orphan drugs face uphill battle in 2020

As patients, clinicians and researchers prepare for Rare Disease Day on February 29 2020, GlobalData’s analysis shows the number of drugs awarded orphan drug designations (ODDs) by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) has declined over the last six years, despite the benefits of these designations in speeding […]
Read more

Agile Therapeutics’ Twirla could carve out meaningful share in US contraceptive market

Agile Therapeutics’ Twirla (ethinyl estradiol + levonorgestrel) could have an edge over competitors based on milder side-effects and a potentially safer profile, says GlobalData, a leading data and analytics company. As the largest contraceptives market, the US will experience moderate growth at a compound annual growth rate (CAGR) of 4.8%, reaching $5.2bn total sales by 2027. This market offers several options, including both on-demand and longer-acting approaches, and has […]
Read more

Latest drug approved for migraine prevention will struggle to compete in a crowded market space

Following the news that the Food and Drug Administration (FDA) has approved Vyepti for the prevention of migraines in adults, Philippa Salter, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, offers her view: “Vyepti becomes the latest FDA approved drug for prevention of migraines in adults, following the approval of Amgen’s Aimovig, Eli Lilly’s Emgality and Teva’s Ajovy all of which were approved in the past two years. “In order to stand out in this crowded market Lundbeck are drawing attention to the improved dosing schedule of every 12 weeks for Vyepti, which they hope will give it a competitive advantage over the other available drugs which require dosing every four […]
Read more

Promising pipeline products anticipated to bolster treatment options for dry eye syndrome

Current treatment options for dry eye syndrome (DES) are limited to artificial tears, mostly on its own for milder forms of DES and in combination with anti-inflammatory and corticosteroid therapies for more severe forms of DES. However, this treatment paradigm is expected to see a significant change in the next ten years thanks to a number of promising therapies currently in pipeline development.    According to GlobalData, there are 52 pipeline products in different stages of development, which include Phase I, II and III products across the nine […]
Read more

Dr Reddy’s takes inorganic route to grow in India, says GlobalData

Following the recent news that Dr Reddy’s Laboratories (DRL) has agreed to acquire Wockhardt Ltd’s select divisions of branded generics business in India, Nepal, Sri Lanka, Bhutan and Maldives for a consideration of INR18.5bn (US$260m); Prashant Khadayate, Practice Head of Healthcare at GlobalData, a leading data and analytics company, offers his view: “Dr Reddy’s has […]
Read more

US dermatophytic onychomycosis market set to reach $676.4m by 2028

The dermatophytic onychomycosis market is expected to grow from $208.8m in 2018 to $676.4m in 2028 within the US, at a compound annual growth rate (CAGR) of 12.5%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Dermatophytic Onychomycosis: US Drug Forecast and Market Analysis to 2028’, states that the US dermatophytic […]
Read more
1 … 101 102 103 104 105 … 110